High dose biotin as treatment for progressive multiple sclerosis
| Autor: | Gary Birnbaum, Jessica Stulc |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male medicine.medical_specialty Immunologic Factors Vitamin b complex Biotin 03 medical and health sciences chemistry.chemical_compound Disability Evaluation 0302 clinical medicine Multiple Sclerosis Relapsing-Remitting Facial Pain Internal medicine medicine Lower extremity weakness Humans Facial pain Treatment Failure Progressive multiple sclerosis business.industry Multiple sclerosis Brain General Medicine Middle Aged Multiple Sclerosis Chronic Progressive medicine.disease Surgery 030104 developmental biology Neurology chemistry Toxicity Vitamin B Complex Female Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Multiple sclerosis and related disorders. 18 |
| ISSN: | 2211-0356 |
| Popis: | Background Published data suggested high dose biotin improved patients with progressive MS. We wished to determine benefits and side effects of administering daily high dose biotin to patients with progressive multiple sclerosis in a large MS specialty clinic. Methods Forty-three patients with progressive multiple scleroses were prescribed pharmaceutical grade biotin as a single daily dose of 300 mg/day. Brain MRIs were performed at baseline and after one year on biotin. Quantitative neurologic exams (EDSS) and blood work monitoring for biotin toxicity were performed at baseline and every three months thereafter. Results High dose biotin was safe, and well tolerated, with no evidence of toxicity on blood work and no new lesions on brain MRIs. None of the patients’ EDSS scores improved. One-third of patients (38–43%) worsened, most often with increased lower extremity weakness, worsened balance, and more falling, with two patients worsening sufficiently to increase their EDSS scores by 0.5. Several worsened patients improved after stopping biotin. Conclusion High dose biotin was safe and well tolerated, but of no demonstrable long-term benefit. More than one-third of patients worsened while on biotin, most likely due to their disease, but in some patients also possibly due to the inability of their injured central nervous systems to respond to the increased metabolic demands induced by biotin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect